Abstract:Background: It is necessary to search for a novel macromolecule, which is used as a targeted drug carrier. Objective: To prepare a new poly-asparagine derivates, namely succinyl-α,β-poly(2-hydroethyl)-D,L-aspartamide (PHEA-Suc) and galactosyl-PHEA-Suc (Gal-PHEA-Suc), and to explore its characterization and cytotoxicity in vitro. Design, time and setting: The in vitro trial was performed in the State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University (Nanjing, Jiangsu, China) from June 2005 to June 2007. Materials: L-aspartic acid, anhydrous N,N-dimethylformamide, lactobionic acid, fluorescein isothiocyanate, dimethyl sulfoxide and MTT were purchased from Sigma Company (USA); Human HeLa cells and HepG2 cells were offered from Shanghai Cell Bank; New-born calf serum was a product of Hangzhou Sijiqing Biocompany; Trypase was purchased from Hyclone Company (USA). Other reagents were domestic analytical pure. Methods: Infrared spectrum, nuclear magnetic resonance, elemental analysis and molecular mass determination were all conducted to investigate the characterization of the material. Tetrazolium bromide colorimetric assay was employed to detect the cytotoxicity of PHEA-suc and Gal-PHEA-suc. Main outcome measures: The structure and cytotoxicity of poly-asparagine derivates carrier. Results: The structures of PHEA-suc and Gal-PHEA-suc were identified using infrared spectrum and nuclear magnetic resonance. Elemental analysis displayed that the succinylation degree of PHEA-suc and Gal-PHEA-suc were 43% (mol/mol), galactosylation degree of Gal-PHEA-suc was 7.6% (mol/mol). Results of in vitro cytotoxicity showed that, both PHEA-suc and Gal-PHEA-suc exhibited few effects on inhibiting the growth of HeLa cells and HepG2 cells. There was no effect action at a concentration of less than 500 mg/L. Conclusion: Poly-asparagine derivates carriers PHEA-suc and Gal-PHEA-suc have low cytotoxicity with -suc active group and -gal target group, so they can be used as ideal target drug carriers.

Synthesis and biological activities of galactose–aspirin conjugate prodrug designed for ADEPT and PMT

Synthesis of an Enzyme—dependent Prodrug and Evaluation of Its Potential for Colon Targeting

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib

Synthesis and in vitro antitumor activity of galactosamine–docetaxel conjugates

Synthesis and Biological Evaluation of Novel Spin Labeled 18Β-Glycyrrhetinic Acid Derivatives

Design and Synthesis of Analogues of Marine Natural Product Galaxamide, an N-methylated Cyclic Pentapeptide, as Potential Anti-Tumor Agent in Vitro

Synthesis, characterization and in vitro trial of poly-asparagine derivates carrier

Aspirin prodrugs: synthesis and hydrolysis of 2-acetoxybenzoate esters of various N-(hydroxyalkyl) amides

Two-step Synthesis of Structure-Diverse D-Galactose Conjugates and Polymeric Prodrugs of Floxuridine Via Controllable Regioselective Enzymatic Acylation of 3′- or 5′-OH Group of Floxuridine

Identification of a potent Nrf2 displacement activator among aspirin-containing prodrugs

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

Preparation, characterization and therapeutic properties of gum arabic-stabilized gallic acid nanoparticles

Galactose-based amphiphilic block copolymers: synthesis, micellization, and bioapplication.

Synthesis of artemisinic acid derived glycoconjugates and their anticancer studies

Novel high-loaded, nanoparticulate and thermally stable macromolecular prodrug design of NSAIDs based on hydroxypropylcellulose

Hepatic-targeting microcapsules construction by self-assembly of bioactive galactose-branched polyelectrolyte for controlled drug release system.

Synthesis, Characterization, and in Vivo Efficacy Evaluation of PGG–docetaxel Conjugate for Potential Cancer Chemotherapy

Design and Synthesis of Aspirin-chalcone Mimic Conjugates as Potential Anticancer Agents

Programmable Repurposing of Existing Drugs as Pharmaceutical Elements for the Construction of Aptamer–Drug Conjugates

Synthesis and performance of alpha, beta-poly [(2-hydroethyl)-D, L-aspartamide]-methotrexate and alpha, beta-poly [(2-hydroethyl)-D, L-aspartamide]-succinic-methotrexate

Galactosylated Α,β-Poly[(2-hydroxyethyl)-l-aspartamide]-bound Doxorubicin